Sunflower Pharmaceutical Group Co.,Ltd

SZSE:002737 Stock Report

Market Cap: CN¥10.4b

Sunflower Pharmaceutical GroupLtd Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Yi Guan

Chief executive officer

CN¥4.8m

Total compensation

CEO salary percentagen/a
CEO tenure6.1yrs
CEO ownershipn/a
Management average tenure3.2yrs
Board average tenure3.6yrs

Recent management updates

Recent updates

There Is A Reason Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Price Is Undemanding

Jan 04
There Is A Reason Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Price Is Undemanding

We Believe That Sunflower Pharmaceutical GroupLtd's (SZSE:002737) Weak Earnings Are A Good Indicator Of Underlying Profitability

Nov 04
We Believe That Sunflower Pharmaceutical GroupLtd's (SZSE:002737) Weak Earnings Are A Good Indicator Of Underlying Profitability

A Look At The Intrinsic Value Of Sunflower Pharmaceutical Group Co.,Ltd (SZSE:002737)

Aug 26
A Look At The Intrinsic Value Of Sunflower Pharmaceutical Group Co.,Ltd (SZSE:002737)

Lacklustre Performance Is Driving Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Low P/E

Jul 19
Lacklustre Performance Is Driving Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Low P/E

Sunflower Pharmaceutical GroupLtd's (SZSE:002737) Shareholders Will Receive A Bigger Dividend Than Last Year

Jun 07
Sunflower Pharmaceutical GroupLtd's (SZSE:002737) Shareholders Will Receive A Bigger Dividend Than Last Year

Earnings Troubles May Signal Larger Issues for Sunflower Pharmaceutical GroupLtd (SZSE:002737) Shareholders

May 06
Earnings Troubles May Signal Larger Issues for Sunflower Pharmaceutical GroupLtd (SZSE:002737) Shareholders

Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Subdued P/E Might Signal An Opportunity

Apr 16
Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Subdued P/E Might Signal An Opportunity

We Ran A Stock Scan For Earnings Growth And Sunflower Pharmaceutical GroupLtd (SZSE:002737) Passed With Ease

Mar 04
We Ran A Stock Scan For Earnings Growth And Sunflower Pharmaceutical GroupLtd (SZSE:002737) Passed With Ease

CEO

Yi Guan (42 yo)

6.1yrs

Tenure

CN¥4,800,000

Compensation

Ms. Yi Guan has been a Non-Independent Director of Sunflower Pharmaceutical Group Co., Ltd. since September 26, 2017 and serves as its General Manager since January 07, 2019. She was awarded the title of H...

Leadership Team

NamePositionTenureCompensationOwnership
Yi Guan
GM & Non-Independent Director6.1yrsCN¥4.80mno data
Chunhong Wu
Financial Manager3.2yrsCN¥774.90kno data
Guangguang Zhou
Board Secretary3.1yrsCN¥436.70kno data
Liang Chen
Deputy General Manager3.2yrsCN¥3.06mno data
Jin Ming Lin
Deputy General Manager5.1yrsCN¥786.00kno data
Xin Ma
Deputy General Manager3.2yrsCN¥1.36mno data
Yang Hai
Deputy General Manager3.2yrsCN¥1.41mno data
Li Chen
Accounting Supervisorno datano datano data

3.2yrs

Average Tenure

43yo

Average Age

Experienced Management: 002737's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yi Guan
GM & Non-Independent Director7.4yrsCN¥4.80mno data
Yanling Guan
Non-Independent Director10.9yrsCN¥1.18mno data
Jingshang Ren
Non-Independent Director7.4yrsCN¥50.00kno data
Yan He
Non-Employee Supervisor7.4yrsno datano data
Chunyan Na
Supervisor4.3yrsno datano data
Yuxiu Guan
Chairman6.1yrsCN¥1.20mno data
Fen Lan
Chairman of the Supervisory Board2.9yrsno datano data
Jianzhong Zhou
Non-Independent Directorless than a yearno datano data
Yang Yang
Non-Independent Directorless than a yearno datano data
Jiajun Miao
Independent Directorless than a yearno datano data
Ying Zhang
Independent Directorless than a yearno datano data
Yan Zhao
Independent directorless than a yearno datano data

3.6yrs

Average Tenure

46yo

Average Age

Experienced Board: 002737's board of directors are considered experienced (3.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/21 07:08
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sunflower Pharmaceutical Group Co.,Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wen Wen ShenAvic Securities Co., Ltd
Bin WuChina Merchants Securities Co. Ltd.